Chemotherapy given before definitive surgery, referred to as neoadjuvant therapy (NAT), can down-stage large tumours and allows for earlier treatment administration for breast cancers with a high risk of systemic recurrence such as HER2+ disease. The gene discussed is ERBB2; the disease is breast cancer.